Biocryst Pharmaceuticals (BCRX) Exchange Rate Effect (2021 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Exchange Rate Effect came in at -$72000.0 in Q1 2026, down 115.96% YoY from $451000.0 in Q1 2025, and little changed on a QoQ basis from -$72000.0 in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Exchange Rate Effect (2021 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 6 years of Exchange Rate Effect data on file, last reported at -$72000.0 in Q1 2026.
- Quarterly Exchange Rate Effect fell 115.96% year-over-year to -$72000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $747000.0 (up 615.17% YoY) and the FY2025 annual result came in at $1.3 million, up 235.68% from the prior year.
- Exchange Rate Effect held at -$72000.0 in Q1 2026, from -$72000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $1.4 million in Q2 2025 to a low of -$1.3 million in Q4 2024.
- A 5-year average of $70000.0 and a median of -$14000.0 in 2022 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2022 — Exchange Rate Effect jumped 16450.0% — and 2024, when it sank 349.81%.
- Tracing BCRX's Exchange Rate Effect over 5 years: stood at $331000.0 in 2022, then surged by 57.7% to $522000.0 in 2023, then sank by 349.81% to -$1.3 million in 2024, then surged by 94.48% to -$72000.0 in 2025, then changed by 0.0% to -$72000.0 in 2026.
- The last three Exchange Rate Effect figures came in at -$72000.0 (Q1 2026), -$72000.0 (Q4 2025), and -$468000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -5.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | -7.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 39.87 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -3.30 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 9.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.45 Bn | 2.10 Bn | 214.41 Mn | -35,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35,000.00 |
| Jun 30, 2026 | -35,000.00 |
| Mar 31, 2026 | -72,000.00 |
| Mar 31, 2026 | -72,000.00 |
| Dec 31, 2025 | -72,000.00 |
| Dec 31, 2025 | -72,000.00 |
| Sep 30, 2025 | -468,000.00 |
| Sep 30, 2025 | -468,000.00 |
| Jun 30, 2025 | 1.36 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 451,000.00 |
| Mar 31, 2025 | 451,000.00 |
| Dec 31, 2024 | -1.30 Mn |
| Dec 31, 2024 | -1.30 Mn |
| Sep 30, 2024 | 851,000.00 |
| Sep 30, 2024 | 851,000.00 |
| Jun 30, 2024 | -143,000.00 |
| Jun 30, 2024 | -143,000.00 |
| Mar 31, 2024 | -340,000.00 |
| Mar 31, 2024 | -340,000.00 |